Last reviewed · How we verify
CO-1.01
CO-1.01 is a poly(ADP-ribose) polymerase (PARP) inhibitor that blocks DNA repair mechanisms in cancer cells, leading to cell death.
CO-1.01 is a poly(ADP-ribose) polymerase (PARP) inhibitor that blocks DNA repair mechanisms in cancer cells, leading to cell death. Used for Ovarian cancer (BRCA-mutated or homologous recombination deficient).
At a glance
| Generic name | CO-1.01 |
|---|---|
| Sponsor | Clovis Oncology, Inc. |
| Drug class | PARP inhibitor |
| Target | PARP (poly(ADP-ribose) polymerase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
PARP inhibitors prevent the repair of single-strand DNA breaks by inhibiting the PARP enzyme. This causes accumulation of DNA damage in cancer cells, particularly those with BRCA mutations or homologous recombination deficiency, triggering apoptosis. CO-1.01 was developed as a PARP inhibitor for oncology applications.
Approved indications
- Ovarian cancer (BRCA-mutated or homologous recombination deficient)
Common side effects
- Nausea
- Anemia
- Fatigue
- Thrombocytopenia
Key clinical trials
- Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma (PHASE2)
- Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors (PHASE1)
- A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) (PHASE2)
- A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CO-1.01 CI brief — competitive landscape report
- CO-1.01 updates RSS · CI watch RSS
- Clovis Oncology, Inc. portfolio CI